Conference Coverage

Skipping surgery is an option for some patients with rectal cancer


 

AT THE GASTROINTESTINAL CANCERS SYMPOSIUM

References

Adoption of nonoperative management has been slow in the United States for a variety of reasons, according to Dr. Paty. “I think the bottom line is that practicing watch and wait, nonoperative management is more difficult for the surgeon. It requires first the judgment that the cancer’s gone. You have to follow the patient longer after radiation; sometimes the complete response will take up to 3 months. And there is also the medical-legal issue of deviating from the standard of care. … So I think it was operationally a difficult thing to do, it didn’t fit with the existing paradigm very well.”

But that is changing as more data roll in. “What’s happened in the last I will say 2-3 years is that there are centers publishing their experience, ours being the largest outside Brazil and the first in North America. Another group in the Netherlands has published a group of about 25 patients,” he explained. “Talking with people at meetings around the world, centers are adopting it, and I think that many leaders in clinical trials in rectal cancer recognize that this option is not only reasonable, but perhaps it’s necessary to inform patients that it is an option.”

Pages

Recommended Reading

Identification of subtypes, mutations in CRC and colon cancer greatly increases survival rates
MDedge Hematology and Oncology
New agent extends progression-free survival in advanced pancreatic cancer
MDedge Hematology and Oncology
FDA approves lanreotide for GEP-NETs after priority review
MDedge Hematology and Oncology
A feasibility study of dignity therapy in patients with stage IV colorectal cancer actively receiving second-line chemotherapy
MDedge Hematology and Oncology
Ramucirumab for advanced gastric or GEJ adenocarcinoma in previously treated patients with disease progression
MDedge Hematology and Oncology
Small victories add up to paradigm shifts for hard-to-treat tumors
MDedge Hematology and Oncology
Stage, lymph node status should drive gastric cancer treatment decisions
MDedge Hematology and Oncology
Microbiota organization influences colorectal cancers
MDedge Hematology and Oncology
Outcomes of stage III colon cancer appear better for aspirin, COX-2 inhibitor users
MDedge Hematology and Oncology
TRIBE update: FOLFOXIRI-bevacizumab boosts survival in metastatic CRC
MDedge Hematology and Oncology